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ABSTRACT 
 
 
Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor of the gastrointestinal tract with a 
clinical spectrum ranging from indolent tumors to tumors with aggressive behavior and poor patient 
survival. The established model for prediction of prognosis for GIST is the NIH risk score, which is 
based on tumor size and mitotic index. Even so, there are difficulties in predicting the clinical outcome 
for individual GIST patients, which may lead to inadequate treatment. The majority of GISTs have 
activating mutations in the genes encoding the tyrosine kinase receptors KIT, or PDGFRA, which are 
considered to be pathogenic events in tumor development. Imatinib, a tyrosine kinase inhibitor (TKI) 
that inhibits KIT, has become an important therapeutic option in addition to surgery.  
 
To identify biomarkers that accurately predict clinical outcome in GIST patients, global gene 
expression profiling was performed based on KIT mutations associated with poor prognosis. Tumor 
material from 16 GISTs was analyzed with expression microarray for identification of multiple 
candidate genes with differential expression related to mutational status. PROM1 was shown to be 
highly expressed in GIST with KIT exon 11 mutations. Detection of PROM1 protein with 
immunohistochemical staining of 204 GISTs arranged in a tissue microarray (TMA) showed that 
PROM1 expression was predominant in gastric GISTs of high-risk type. Multivariate Cox analysis 
showed that PROM1 expression was significantly associated with poor prognosis and short patient 
survival, independently of NIH risk score. To evaluate the usefulness of immunohistochemical 
biomarkers for prognostication of GIST, we performed a comprehensive study of 14 biomarkers in 
205 GISTs in a TMA. There was a significant correlation between expression of CA2, CDKN2A, 
CXCL12, EPHA4, FHL1, and DPP4 protein and survival. Furthermore, survival analysis using Cox 
regression showed that CA2, EPHA4, and FHL1 provided prognostic information additional to that 
from the NIH risk score. Construction of a decision-tree model combining NIH risk and expression of 
biomarkers further improved the prediction of patient survival. GISTs are effectively treated with 
surgery and imatinib, but some patients are refractory and develop drug resistance. We have 
investigated the prerequisites for alternative treatment strategies with peptide receptor-mediated 
radiotherapy (PRRT), by analyzing the expression of somatostatin receptors (SSTRs) and uptake of 
radiolabeled somatostatin analogs in GIST. Analysis of 34 GISTs with pPCR and 
immunohistochemistry showed expression of SSTR1 and SSTR2. Primary cultures established from 
GIST showed specific binding and internalization of 
177
Lu-octreotate. Diagnostic imaging with 
111
In-
octreotide showed tumor uptake of 
111
In in 3/6 GIST patients in vivo. Tumor-to-blood activity ratios 
for 
111
In measured in biopsies from excised tumor tissue showed ratios that may be adequate for 
therapy.  
 
We conclude that the expression of PROM1 in GIST may be used as a prognosticator of patient 
survival and may provide a therapeutic target. Several immunohistochemical biomarkers provide 
additional prognostic information in addition to NIH risk score and may be useful in constructing 
decision-trees for improved prognostic accuracy for GIST patients. Binding and uptake of radiolabeled 
somatostatin analogs via SSTR enable tumor imaging and targeted therapy in selected GIST patients.  
 
 
Key words: Gastrointestinal stromal tumor (GIST); KIT; Biomarker; PROM1 (CD133), Somatostatin receptor 
(SSTR); Peptide receptor-mediated radiotherapy (PRRT); Expression profiling; Immunohistochemistry;  
Tissue microarray (TMA); Survival analysis 
 
ISBN 978-91-628-8437-6                              Göteborg 2012 
